Lupin, a pharmaceutical major, has completed its acquisition of Visufarma B.V. (VISUfarma), an european specialty pharmaceutical company focused on ophthalmology, from GHO Capital Partners LLP (GHO). Lupin with the acquisition aims to expand its specialty care portfolio and strengthen its presence in Europe. The integration of Visufarma has significantly expanded Lupin’s ophthalmology portfolio to over 60 branded products spanning dry eye, glaucoma, eyelid hygiene, blepharitis, retinal health and specialty nutraceuticals.
Lupin shares declined 2.5 per cent in early trade on 2 April after the company declared that its subsidiary will acquire a minority stake in Multicare Pharmaceuticals Philippines, Inc. (MPPI). Vinita Gupta, CEO, Lupin, said, “The Visufarma acquisition marks a very exciting milestone for Lupin, adding a differentiated portfolio of more than 60 innovative eye health products supported by an established commercial infrastructure. Beyond being immediately accretive, this strategic acquisition will also expand our presence across Europe and accelerate the build-out of our specialty franchise.”
Paolo Cioccetti, CEO Italy, Visufarma, added, “We are thrilled to embark on this next chapter with Lupin. Their global expertise, vision and commitment to ophthalmology make them the ideal partner to take VISUfarma to the next level. Together, we are confident that we can make a significant impact in advancing eye care across Europe and beyond.